A kind of Euglena rich in beta-1,3-glucan for controlling blood sugar and reducing blood lipids and its preparation method and application

By optimizing the culture conditions and screening methods, the content of β-1,3-glucan in nude algae is improved, and the problems of low β-1,3-glucan content and low production efficiency in the prior art are solved. It achieves efficient and safe production and is suitable for the application of functional foods and health products.

CN118599668BActive Publication Date: 2024-11-15ZAOCHEN (SHANDONG) BIOLOGICAL ENG CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411005648.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-15
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

In the prior art, the β-1,3-glucan content of nude algae is low and the production efficiency is low, which limits its application in functional foods and health products. The traditional methods require complex genetic engineering technology and are costly. And there are security issues.

Method used

By optimizing the culture conditions and screening methods of nude algae, the content of β-1,3-glucan in nude algae was improved. The fermentation and culture was carried out by light-free heterotrophic culture medium and fermentation tank, and combined with induction treatment, the β- 1,3-Glucan yield and production efficiency avoid the complexity and safety risks of genetic engineering.

Benefits of technology

It has achieved efficient production of nude algae rich in β-1,3-glucan, with biomass up to 108 g/L and β-1,3-glucan content up to 650 mg/g, reducing production costs and increasing The safety and market acceptance of the product are suitable for sugar control, lipid reduction and weight management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118599668B_ABST
    Figure CN118599668B_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of naked algae, and in particular to a naked algae rich in β‑1,3‑glucan for controlling blood sugar and reducing blood lipids, and a preparation method and application thereof. A naked algae with high β‑1,3‑glucan production is provided, and the naked algae is Euglena gracilis ZC‑1004, and the deposit number is GDMCC No: 63861. The naked algae has a high biomass density, a fast growth rate, and a high β‑1,3‑glucan content under light-free heterotrophic conditions. The preparation method includes optimizing culture conditions and efficient screening, and obtaining naked algae with high β‑1,3‑glucan production through culture medium and environmental control. The naked algae showed significant blood sugar and lipid control and weight management effects in animal experiments, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of euglena, and in particular to a sugar-controlling and lipid-lowering euglena rich in beta-1,3-glucan, and a preparation method and application thereof. Background Art

[0002] With the changes in modern lifestyles, obesity and related metabolic diseases such as diabetes and hyperlipidemia are becoming increasingly serious. Although there are various drugs and health products on the market for controlling weight and blood sugar, the effects vary, and some products have side effects. Therefore, finding natural, safe, and effective products for controlling weight and blood sugar has become a hot topic in research.

[0003] Euglena gracilis is a single-cell green algae with unique nutrients and bioactive substances, among which β-1,3-glucan is an important component. β-1,3-glucan has been shown to have multiple biological activities such as immune regulation, anti-tumor, and antioxidant. Therefore, using Euglena to produce rich β-1,3-glucan and applying it to blood sugar and lipid control and weight management has important application prospects.

[0004] In the prior art, the β-1,3-glucan content of Euglena is low and the production efficiency is not high, which limits its application in functional foods and health products. Therefore, the development of a high-yield β-1,3-glucan Euglena strain and its efficient preparation method is of great significance for promoting the application of Euglena in sugar control, lipid reduction and weight management.

[0005] Although some studies have been devoted to increasing the content of β-1,3-glucan in euglena, these methods usually require complex genetic engineering technology, which is complicated to operate, costly, and sometimes brings uncertain safety issues. Therefore, it is particularly important to develop a method for efficiently producing β-1,3-glucan-rich products without genetic engineering. This can not only simplify the operation and reduce costs, but also improve the safety and market acceptance of the product.

[0006] The present invention successfully increases the content of β-1,3-glucan in euglena by optimizing the culture conditions and screening method of euglena, and significantly improves the production efficiency. The method is not only simple and efficient, but also low in cost and high in safety, and has broad application prospects. Summary of the invention

[0007] The main purpose of the present invention is to provide a method for efficiently producing euglena rich in β-1,3-glucan and a preparation method thereof, which can effectively solve the problems in the prior art.

[0008] To achieve the above object, the technical solution adopted by the present invention is:

[0009] A method for efficiently producing β-1,3-glucan-rich euglena, wherein the euglena is Euglena gracilis ZC-1004, the preservation number is GDMCC No: 63861, the preservation center is Guangdong Microbial Culture Collection Center, and the preservation date is October 8, 2023.

[0010] Furthermore, the method for efficiently producing euglena rich in β-1,3-glucan comprises the following steps:

[0011] S1. Provide the original strain of Euglena gracilis;

[0012] S2. The original algae strain is cultured in a light-free heterotrophic medium to optimize the culture conditions;

[0013] S3. Pick out fast-growing single algae for purification and subculture, and screen to obtain naked algae rich in β-1,3-glucan.

[0014] Furthermore, in step S2, the pH value of the culture medium is 3.5-7.0, and the culture temperature is 20-30°C.

[0015] Furthermore, in step S2, a nutrient formula is used to promote the rapid growth of euglena and the efficient accumulation of β-1,3-glucan.

[0016] Furthermore, the euglena is cultured under light-free heterotrophic conditions, with high biomass density and fast growth rate.

[0017] Furthermore, the β-1,3-glucan content of the euglena is 400 mg / g-500 mg / g.

[0018] Furthermore, through induction conditions, the β-1,3-glucan content of the euglena was further increased to 650 mg / g.

[0019] Furthermore, the euglena was fermented and cultured in a fermenter for 72 hours, with a biomass of 85 g / L, a β-1,3-glucan content of 650 mg / g, and a β-1,3-glucan yield of 0.77 g / (Lh).

[0020] Furthermore, after 12 hours of induction treatment, the biomass of Euglena reached 108 g / L, the β-1,3-glucan content was 680 mg / g, and the β-1,3-glucan yield was 0.87 g / (Lh) per liter of fermentation culture medium in the fermenter.

[0021] Furthermore, the application includes controlling sugar and lipid levels and controlling weight gain.

[0022] Compared with the prior art, the present invention has the following improvements:

[0023] 1. High yield: The provided euglena strain can reach a biomass of 108 g / L and a β-1,3-glucan content of 650 mg / g after fermentation in a fermenter for 72 hours, which is significantly higher than the existing technical level.

[0024] 2. Low cost: No complicated genetic engineering techniques are required, efficient production can be achieved by optimizing culture conditions, thus reducing production costs.

[0025] 3. High safety: It avoids the safety issues caused by genetic engineering, and the product is more natural and safe.

[0026] 4. Wide application: Rich in β-1,3-glucan, it can be used for blood sugar control, lipid reduction and weight management, with significant effects, and is suitable for the field of functional foods and health products. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Figure 2 is a graph showing changes in body weight during the intervention period of the present invention (* represents comparison with the HFD group, *, p<0.05; **, p<0.01).

[0028] Figure 2 This is a graph showing the change in subcutaneous fat coefficient after 9 weeks of intervention by the present invention.

[0029] Figure 3 This is a schematic diagram of triglyceride content in adipose tissue after 9 weeks of intervention according to the present invention.

[0030] Figure 4 This is an area graph of the glucose tolerance curve after 9 weeks of intervention by the present invention.

[0031] Figure 5 This is a glucose tolerance curve chart after 9 weeks of intervention by the present invention.

[0032] Figure 6 This is a fasting blood sugar chart after 9 weeks of intervention by the present invention. DETAILED DESCRIPTION

[0033] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0034] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.

[0035] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, and c can be single or multiple.

[0036] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0037] The terms used in the embodiments of the present application are only for the purpose of describing the embodiments, and are not intended to limit the present application. The singular forms "a", "an" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0038] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also indicate the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass in the embodiment description of the present application can be a mass unit known in the chemical industry such as µg, mg, g, kg, etc.

[0039] The terms "first" and "second" are used only for descriptive purposes to distinguish objects such as substances from each other, and should not be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. For example, without departing from the scope of the embodiments of the present application, the first XX may also be referred to as the second XX, and similarly, the second XX may also be referred to as the first XX. Thus, features defined as "first" and "second" may explicitly or implicitly include one or more of the features.

[0040] Example 1: Preparation method of euglena rich in β-1,3-glucan

[0041] Original algae strain: The original algae strain of Euglena gracilis is provided as the basic algae strain.

[0042] Optimization of culture conditions: The original algae strain was suspended in a light-free heterotrophic culture medium, the pH value of the culture medium was adjusted to 5.0, and the culture temperature was set to 30°C. The culture medium contained appropriate amounts of nitrogen, phosphorus, carbon and trace elements to promote the rapid growth of Euglena and the accumulation of β-1,3-glucan.

[0043] Efficient screening: Pick fast-growing single algae for purification and subculture, and finally obtain a euglena strain rich in β-1,3-glucan through multiple screening. The preservation number of this high-yield algae strain is GDMCC No: 63861.

[0044] Example 2: Fermentation culture of high-yield euglena

[0045] Culture conditions:

[0046] The high-yield Euglena ZC-1004 was inoculated in a light-free heterotrophic culture medium, the pH value of the culture medium was adjusted to 5.0, and the culture temperature was set to 30°C. The culture medium in the fermenter was evenly mixed and aerated to ensure the best growth environment for the algae strain.

[0047] Fermentation culture:

[0048] Fermentation was carried out in a fermenter for 72 hours. After the fermentation, the biomass and β-1,3-glucan content in the culture medium were measured. The results showed that the biomass was 85 g / L, the β-1,3-glucan content was 650 mg / g, and the β-1,3-glucan yield was 0.77 g / (Lh).

[0049] Induction treatment:

[0050] The fermentation culture medium was induced for 12 hours to further increase the content of β-1,3-glucan. After treatment, the biomass and β-1,3-glucan content of Euglena were measured. The results showed that the biomass of Euglena reached 108g / L, the β-1,3-glucan content was 680 mg / g, and the β-1,3-glucan yield was 0.87 g / (Lh).

[0051] Example 3: Experiment on Controlling Sugar and Lipid and Managing Weight

[0052] Experimental design: Eight-week-old mice were divided into three groups: control group (CON), high-fat diet group (HFD), and high-fat diet + 0.1 g / kg body weight / day Euglena intervention group (HEL). The control group was fed with normal feed, and the other two groups were fed with high-fat diet.

[0053] Intervention process: After the obesity model was successfully established, intervention was continued in each group. The HEL group was fed 0.1 g / kg body weight of Euglena powder every day. During the intervention period, the body weight of the mice was measured every week.

[0054] Result analysis:

[0055] 1. Weight changes: Starting from the 5th week of intervention, Euglena significantly reduced the weight gain of mice; starting from the 6th week, Euglena significantly reduced the weight of mice and inhibited the obesity process.

[0056] 2. Body fat and liver fat deposition: After 9 weeks of intervention, the subcutaneous fat and liver fat deposition of mice were measured. The results showed that Euglena significantly reduced subcutaneous fat and liver fat deposition, and the body fat content of mice returned to normal levels.

[0057] 3. Blood lipid and blood sugar levels: After 9 weeks of intervention, the blood lipid and blood sugar levels of mice were measured. The results showed that Euglena significantly increased the level of high-density lipoprotein cholesterol (HDL-C), reduced fasting blood sugar and glucose tolerance curve area, and significantly improved blood lipid and blood sugar levels.

[0058] Example 4: Liver protection and lipid-lowering experiment

[0059] Experimental design: Mice under high-fat diet intervention were divided into a control group and a Euglena intervention group (fed with 0.1 g / kg body weight Euglena powder per day), and the intervention lasted for 9 weeks. The specific steps are as follows:

[0060] Grouping: Eight-week-old mice were randomly divided into a control group (CON) and a Euglena intervention group (HEL), with 10 mice in each group.

[0061] Dietary intervention: The control group was fed with normal feed, and the high-fat diet + euglena meal intervention group (HEL) was fed with high-fat feed and supplemented with 0.1 g / kg body weight of euglena meal per day.

[0062] Body weight monitoring: The body weight of mice was measured weekly.

[0063] Intervention duration: The intervention lasted 9 weeks.

[0064] Result analysis:

[0065] 1. Fat cell size and number: The size of fat cells in the mice in the Euglena intervention group was significantly reduced, and fat deposition was reduced. The average diameter of fat cells in the control group mice was 50μm, while the average diameter of fat cells in the Euglena intervention group mice was 30μm.

[0066] 2. Fat deposition in the liver: The fat deposition in the liver of mice supplemented with Euglena powder was significantly improved, and the triglyceride content in adipocytes was reduced. The liver fat content of mice in the control group was 120 mg / g, while the liver fat content of mice in the Euglena intervention group was 80 mg / g.

[0067] 3. Blood lipid levels: The mice in the Euglena intervention group significantly increased their high-density lipoprotein cholesterol (HDL-C) levels and reduced their low-density lipoprotein cholesterol (LDL-C) levels. The HDL-C level increased from 40 mg / dL in the control group to 55 mg / dL, and the LDL-C level decreased from 110 mg / dL in the control group to 75 mg / dL.

[0068] Example 5: Experiment of assisting in lowering blood sugar

[0069] Experimental design: The mice under high-fat diet intervention were divided into a control group and a euglena intervention group (fed with 0.1 g / kg body weight of euglena powder per day), and the intervention lasted for 9 weeks. The specific steps are as follows:

[0070] Grouping: Eight-week-old mice were randomly divided into a control group (CON) and a Euglena intervention group (HEL), with 10 mice in each group.

[0071] Dietary intervention: The control group was fed with normal feed, and the high-fat diet + euglena meal intervention group (HEL) was fed with high-fat feed and supplemented with 0.1 g / kg body weight of euglena meal per day.

[0072] Body weight monitoring: The body weight of mice was measured weekly.

[0073] Intervention duration: The intervention lasted 9 weeks.

[0074] Result analysis:

[0075] 1. Fasting blood glucose: The fasting blood glucose level of mice in the Euglena intervention group was significantly reduced, from 180 mg / dL before the intervention to 120 mg / dL. The fasting blood glucose level of mice in the control group did not change significantly before and after the intervention and remained at 180 mg / dL.

[0076] 2. Glucose tolerance: The glucose tolerance test showed that the glucose tolerance of mice in the Euglena intervention group was significantly improved, and the blood glucose curve area (AUC) decreased from 4000 in the control group to 2500.

[0077] 3. Blood sugar control: The blood sugar levels of mice supplemented with Euglena powder were significantly improved, and even returned to the level of normal mice.

[0078] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A euglena rich in β-1,3-glucan, characterized in that: The euglena is Euglena gracilis ZC-1004, the preservation number is GDMCC No: 63861, and the preservation center is Guangdong Microbial Culture Collection Center.

2. Use of the euglena according to claim 1 in controlling blood sugar and lipids and controlling weight gain.